283 related articles for article (PubMed ID: 30576565)
1. Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer.
Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Hori S; Morizawa Y; Tatsumi Y; Hasegawa M; Fujii T; Fujimoto K
J Radiat Res; 2019 Mar; 60(2):270-280. PubMed ID: 30576565
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer].
Du XX; Yang H; Zhang HJ; Li LA; Fan WS; Meng YG
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):679-686. PubMed ID: 29060966
[No Abstract] [Full Text] [Related]
4. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy.
Tsui G; Gillan C; Pond G; Catton C; Crook J
Cancer J; 2005; 11(2):122-32. PubMed ID: 15969987
[TBL] [Abstract][Full Text] [Related]
5. [A randomized study of intensity-modulated radiation therapy versus three dimensional conformal radiation therapy for pelvic radiation in patients of post-operative treatment with gynecologic malignant tumor].
Ni J; Yin ZM; Yuan SH; Liu NF; Li L; Xu XX; Lou HM
Zhonghua Fu Chan Ke Za Zhi; 2017 Mar; 52(3):168-174. PubMed ID: 28355688
[No Abstract] [Full Text] [Related]
6. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.
Bruner DW; Hunt D; Michalski JM; Bosch WR; Galvin JM; Amin M; Xiao C; Bahary JP; Patel M; Chafe S; Rodrigues G; Lau H; Duclos M; Baikadi M; Deshmukh S; Sandler HM
Cancer; 2015 Jul; 121(14):2422-30. PubMed ID: 25847819
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study.
Rathod S; Gupta T; Ghosh-Laskar S; Murthy V; Budrukkar A; Agarwal J
Oral Oncol; 2013 Jun; 49(6):634-42. PubMed ID: 23562564
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.
Löser A; Beyer B; Carl CO; Löser B; Nagaraj Y; Frenzel T; Petersen C; Krüll A; Graefen M; Schwarz R
Strahlenther Onkol; 2019 May; 195(5):374-382. PubMed ID: 30390115
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
10. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
12. Combined intensity-modulated radiation therapy vs. three-dimensional highly conformal radiotherapy after (125)I prostate permanent seed brachytherapy: a comparative treatment planning study.
Zilli T; Boudreau C; Filion EJ; Donath D; Taussky D
Brachytherapy; 2011; 10(5):416-20. PubMed ID: 21316311
[TBL] [Abstract][Full Text] [Related]
13. Quality of Life after post-prostatectomy intensity modulated radiation therapy to the prostate bed with or without the use of gold fiducial markers for image guidance or higher total radiotherapy doses.
Abuodeh YA; Naghavi AO; Juan TH; Ma Z; Wilder RB
Int Braz J Urol; 2017; 43(4):628-637. PubMed ID: 28379660
[TBL] [Abstract][Full Text] [Related]
14. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
15. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer.
Zelefsky MJ; Poon BY; Eastham J; Vickers A; Pei X; Scardino PT
Radiother Oncol; 2016 Jan; 118(1):85-91. PubMed ID: 26780999
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K
BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855
[TBL] [Abstract][Full Text] [Related]
19. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy.
Namiki S; Ishidoya S; Tochigi T; Kawamura S; Kuwahara M; Terai A; Yoshimura K; Numata I; Satoh M; Saito S; Takai Y; Yamada S; Arai Y
Jpn J Clin Oncol; 2006 Apr; 36(4):224-30. PubMed ID: 16537689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
